Sees FY27 Revenue Growth 7%-8% from $5.9B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Sees FY27 revenue growth 7%-8% from $5.9B, consensus $6.31B. Sees FY27 CapEx $375M.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STE
About STE
STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
STERIS Earnings Preview: Revenue Growth of 9.2%
- Revenue Performance: STERIS reported $1.50 billion in revenue last quarter, reflecting a 9.2% year-over-year increase, which slightly exceeded analysts' expectations but indicates mixed performance amid market uncertainties.
- Market Expectations: This quarter, analysts anticipate STERIS's revenue to grow by 7.7% year-over-year, an improvement from the 4.3% growth recorded in the same quarter last year, suggesting potential for recovery in growth.
- Analyst Confidence: Over the past 30 days, most analysts covering STERIS have reaffirmed their revenue estimates, indicating confidence in the company's stability heading into earnings, despite having missed Wall Street's revenue estimates multiple times over the past two years.
- Peer Performance: In the surgical equipment and consumables sector, Zimmer Biomet reported a 9.3% revenue growth while CONMED experienced a 1.3% decline, providing insights into STERIS's potential performance in the upcoming earnings report.
See More
STERIS plc Reports Record Fiscal 2026 Earnings Growth
- Significant Revenue Growth: STERIS plc achieved a 9% revenue growth in fiscal 2026, with a 7% organic growth on a constant currency basis, demonstrating strong market performance despite an 80 basis point impact from tariffs.
- Profitability Improvement: The company reported a 10% increase in adjusted earnings per share for Q4, reaching $2.83, despite facing approximately $10 million in tariff impacts, showcasing effective strategies in cost control and pricing.
- Share Buyback Plan: The Board approved a new $1 billion buyback authorization, expecting to repurchase $200 million to $300 million in shares annually, reflecting confidence in future cash flows and a commitment to enhancing shareholder value.
- Optimistic Future Outlook: Management anticipates revenue growth of 7% to 8% for fiscal 2027, with plans for approximately 50 basis points EBIT margin expansion, indicating strategic positioning in ongoing investments and market demand management.
See More
STERIS Reports Significant Growth in Fiscal Year 2026
- Revenue Growth: STERIS reported a 9% increase in fiscal year 2026 revenue from continuing operations, reaching $5.9 billion, driven by growth in procedure volumes and a diversified customer base, indicating strong market demand and business resilience.
- Earnings Per Share Improvement: The adjusted EPS for fiscal year 2026 rose to $10.17, up 10.3% from $9.22 in fiscal year 2025, reflecting significant enhancements in profitability and boosting investor confidence in the company's financial health.
- Share Repurchase Program: The Board of Directors has authorized a new $1 billion share buyback program aimed at enhancing per-share earnings, demonstrating the company's commitment to shareholder value and confidence in future growth prospects.
- Optimistic Future Outlook: The company anticipates a revenue increase of 7-8% for fiscal year 2027 and plans to invest $60 million in a new sterility assurance manufacturing plant in Mentor, Ohio, to support long-term customer demand, showcasing strategic decisions to expand production capacity and market share.
See More
STERIS Announces Quarterly Dividend Distribution
- Quarterly Dividend Announcement: STERIS plc has declared a quarterly dividend of $0.63 per share, payable on June 26, 2026, which aims to enhance shareholder returns and attract more investor interest.
- Record Date for Shareholders: The record date for the dividend payment is set for June 8, 2026, ensuring that shareholders holding stock by this date will receive the dividend, reflecting the company's commitment to shareholder interests.
- Transparent Tax Information: The company provides additional information regarding the U.S. tax treatment of dividends, including required Form 8937, aimed at improving shareholders' understanding of tax compliance and enhancing corporate transparency.
- Industry Leadership Position: As a leading global provider of infection prevention products and services, STERIS's dividend distribution strategy not only reflects its robust financial health but may also further solidify its leadership position in the healthcare industry.
See More
Profitable Companies May Not Last
- Inter Parfums Performance: Inter Parfums (NASDAQ:IPAR) has a trailing 12-month GAAP operating margin of 18.2%, but its modest revenue base of $1.49 billion limits fixed cost leverage, with demand expected to remain flat over the next 12 months, indicating growth challenges ahead.
- STERIS Investment Risks: STERIS (NYSE:STE) shows a trailing 12-month GAAP operating margin of 17.2%, yet its 5% return on invested capital highlights management's difficulties in identifying attractive investment opportunities, while its current share price of $223.44 reflects a forward P/E of 20.7, suggesting potential overvaluation risks.
- Northern Oil and Gas Growth Potential: Northern Oil and Gas (NYSE:NOG) has achieved an exceptional 28.9% annual revenue growth over the past decade, boasting a best-in-class gross margin of 81.1%, with its current stock price of $26.51 indicating a forward P/E of 7.8, showcasing strong cash flow and investment flexibility.
- Market Dynamics Shift: The current market is rapidly distinguishing quality stocks from overvalued ones, with an AI system successfully identifying several potential winners, prompting investors to pay close attention to these shifts to seize investment opportunities.
See More
STERIS to Host Conference Call for FY 2026 Results
- Conference Call Announcement: STERIS plc will host a conference call on May 12, 2026, at 9:00 a.m. ET to discuss its fiscal 2026 fourth quarter and full year results, demonstrating the company's commitment to transparency and investor communication.
- Earnings Release Timing: The company will issue its financial results after the U.S. market closes on May 11, 2026, ensuring that investors receive the latest financial information prior to the call, thereby enhancing market focus on its performance.
- Replay Service Availability: For investors unable to listen live, STERIS offers a replay of the conference call starting at 12:00 p.m. ET on May 12, 2026, which enhances interaction and information flow between the company and its investors.
- Global Business Context: As a leading global provider of infection prevention products and services, STERIS's conference call not only showcases its leadership in the healthcare sector but also reflects its attention to future market trends and strategic responses.
See More
STERIS Earnings Preview: Revenue Growth of 9.2%
- Revenue Performance: STERIS reported $1.50 billion in revenue last quarter, reflecting a 9.2% year-over-year increase, which slightly exceeded analysts' expectations but indicates mixed performance amid market uncertainties.
- Market Expectations: This quarter, analysts anticipate STERIS's revenue to grow by 7.7% year-over-year, an improvement from the 4.3% growth recorded in the same quarter last year, suggesting potential for recovery in growth.
- Analyst Confidence: Over the past 30 days, most analysts covering STERIS have reaffirmed their revenue estimates, indicating confidence in the company's stability heading into earnings, despite having missed Wall Street's revenue estimates multiple times over the past two years.
- Peer Performance: In the surgical equipment and consumables sector, Zimmer Biomet reported a 9.3% revenue growth while CONMED experienced a 1.3% decline, providing insights into STERIS's potential performance in the upcoming earnings report.
See More
STERIS plc Reports Record Fiscal 2026 Earnings Growth
- Significant Revenue Growth: STERIS plc achieved a 9% revenue growth in fiscal 2026, with a 7% organic growth on a constant currency basis, demonstrating strong market performance despite an 80 basis point impact from tariffs.
- Profitability Improvement: The company reported a 10% increase in adjusted earnings per share for Q4, reaching $2.83, despite facing approximately $10 million in tariff impacts, showcasing effective strategies in cost control and pricing.
- Share Buyback Plan: The Board approved a new $1 billion buyback authorization, expecting to repurchase $200 million to $300 million in shares annually, reflecting confidence in future cash flows and a commitment to enhancing shareholder value.
- Optimistic Future Outlook: Management anticipates revenue growth of 7% to 8% for fiscal 2027, with plans for approximately 50 basis points EBIT margin expansion, indicating strategic positioning in ongoing investments and market demand management.
See More
STERIS Reports Significant Growth in Fiscal Year 2026
- Revenue Growth: STERIS reported a 9% increase in fiscal year 2026 revenue from continuing operations, reaching $5.9 billion, driven by growth in procedure volumes and a diversified customer base, indicating strong market demand and business resilience.
- Earnings Per Share Improvement: The adjusted EPS for fiscal year 2026 rose to $10.17, up 10.3% from $9.22 in fiscal year 2025, reflecting significant enhancements in profitability and boosting investor confidence in the company's financial health.
- Share Repurchase Program: The Board of Directors has authorized a new $1 billion share buyback program aimed at enhancing per-share earnings, demonstrating the company's commitment to shareholder value and confidence in future growth prospects.
- Optimistic Future Outlook: The company anticipates a revenue increase of 7-8% for fiscal year 2027 and plans to invest $60 million in a new sterility assurance manufacturing plant in Mentor, Ohio, to support long-term customer demand, showcasing strategic decisions to expand production capacity and market share.
See More
STERIS Announces Quarterly Dividend Distribution
- Quarterly Dividend Announcement: STERIS plc has declared a quarterly dividend of $0.63 per share, payable on June 26, 2026, which aims to enhance shareholder returns and attract more investor interest.
- Record Date for Shareholders: The record date for the dividend payment is set for June 8, 2026, ensuring that shareholders holding stock by this date will receive the dividend, reflecting the company's commitment to shareholder interests.
- Transparent Tax Information: The company provides additional information regarding the U.S. tax treatment of dividends, including required Form 8937, aimed at improving shareholders' understanding of tax compliance and enhancing corporate transparency.
- Industry Leadership Position: As a leading global provider of infection prevention products and services, STERIS's dividend distribution strategy not only reflects its robust financial health but may also further solidify its leadership position in the healthcare industry.
See More
Profitable Companies May Not Last
- Inter Parfums Performance: Inter Parfums (NASDAQ:IPAR) has a trailing 12-month GAAP operating margin of 18.2%, but its modest revenue base of $1.49 billion limits fixed cost leverage, with demand expected to remain flat over the next 12 months, indicating growth challenges ahead.
- STERIS Investment Risks: STERIS (NYSE:STE) shows a trailing 12-month GAAP operating margin of 17.2%, yet its 5% return on invested capital highlights management's difficulties in identifying attractive investment opportunities, while its current share price of $223.44 reflects a forward P/E of 20.7, suggesting potential overvaluation risks.
- Northern Oil and Gas Growth Potential: Northern Oil and Gas (NYSE:NOG) has achieved an exceptional 28.9% annual revenue growth over the past decade, boasting a best-in-class gross margin of 81.1%, with its current stock price of $26.51 indicating a forward P/E of 7.8, showcasing strong cash flow and investment flexibility.
- Market Dynamics Shift: The current market is rapidly distinguishing quality stocks from overvalued ones, with an AI system successfully identifying several potential winners, prompting investors to pay close attention to these shifts to seize investment opportunities.
See More
STERIS to Host Conference Call for FY 2026 Results
- Conference Call Announcement: STERIS plc will host a conference call on May 12, 2026, at 9:00 a.m. ET to discuss its fiscal 2026 fourth quarter and full year results, demonstrating the company's commitment to transparency and investor communication.
- Earnings Release Timing: The company will issue its financial results after the U.S. market closes on May 11, 2026, ensuring that investors receive the latest financial information prior to the call, thereby enhancing market focus on its performance.
- Replay Service Availability: For investors unable to listen live, STERIS offers a replay of the conference call starting at 12:00 p.m. ET on May 12, 2026, which enhances interaction and information flow between the company and its investors.
- Global Business Context: As a leading global provider of infection prevention products and services, STERIS's conference call not only showcases its leadership in the healthcare sector but also reflects its attention to future market trends and strategic responses.
See More
